title: The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse.
abstract: Liver X receptor (LXR) ligands are currently being evaluated as potential therapeutic agents for the treatment of low HDL. The LXR ligand T0901317 elevates ATP binding cassette transporter A1 (ABCA1) and HDL levels in animal models and induces moderate lipogenesis through upregulation of sterol regulatory element binding protein 1c (SREBP1c). Because insulin may also regulate lipogenesis through SREBP1c and fatty acid synthase (FAS), we investigated the effect of an LXR ligand in hyperinsulinemic mice. Administration of T0901317 to male db/db mice for 12 days resulted in a more severe hypertriacylglycerolemia and hepatic triacylglycerol accumulation than observed in nondiabetic mice. The LXR target genes ABCA1, SREBP1c, FAS, and stearoyl-CoA desaturase 1 were upregulated by T0901317 treatment in both diabetic db/db and nondiabetic C57BLKS mice. Changes in lipogenic gene expression were independent of mouse strain, indicating that the severe lipogenesis observed in LXR ligand-treated db/db mice was not due to additive effects of insulin on lipogenic gene expression. Phosphoenolpyruvate carboxykinase expression was suppressed, suggesting that a shift from gluconeogenesis toward lipogenesis could partially explain our observations in db/db mice. Our data suggest that LXR ligands that have effects on both fatty acid and carbohydrate metabolism should be carefully evaluated in obesity, insulin, and leptin resistance.
authors.affiliation: Discovery Research, CV Therapeutics, Inc., 3172 Porter Dr., Palo Alto, CA 94304, USA. jeffrey.chisholm@cvt.com
authors.forename: Jeffrey W
authors.initials: JW
authors.lastname: Chisholm
authors.forename: Jenny
authors.initials: J
authors.lastname: Hong
authors.forename: Scott A
authors.initials: SA
authors.lastname: Mills
authors.forename: Richard M
authors.initials: RM
authors.lastname: Lawn
mesh_terms: D000818:Animals; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001835:Body Weight / Q000187:drug effects; D002784:Cholesterol / Q000096:biosynthesis / Q000097:blood; D003920:Diabetes Mellitus / Q000097:blood / Q000201:enzymology / Q000378:metabolism*; D004195:Disease Models, Animal; D006845:Hydrocarbons, Fluorinated; D007328:Insulin / Q000097:blood; D008024:Ligands; D008055:Lipids / Q000096:biosynthesis* / Q000097:blood; D008074:Lipoproteins / Q000096:biosynthesis / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009929:Organ Size / Q000187:drug effects; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism*; D013449:Sulfonamides; D014280:Triglycerides / Q000032:analysis / Q000097:blood; D005466:Fluorocarbons; D000096926:Benzenesulfonamides
chemical_list: D000924:Anticholesteremic Agents; D002784:Cholesterol; D006845:Hydrocarbons, Fluorinated; D007328:Insulin; D008024:Ligands; D008055:Lipids; D008074:Lipoproteins; D018160:Receptors, Cytoplasmic and Nuclear; D013449:Sulfonamides; D014280:Triglycerides; C423915:T0901317; D005466:Fluorocarbons; D000096926:Benzenesulfonamides; C030104:lipoprotein cholesterol